Biosynthesis of silver nanoparticles (CTNP's) by Clitoria ternatea flower in the aqueous extract was investigated. Synthesized nanoparticles were characterized by using UV-Visible spectroscopy, followed by DLS, Zeta potential, XRD, FTIR, SEM, and AFM. The biocompatibility nature of CTNP's was determined using erythrocytes model system. Cytotoxicity of CTNP's against MCF-7 and EAC cells were determined by using MTT and Trypan blue exclusion method and their IC50 was found to be 19.37 µg/mL and 24 µg/mL. Cytotoxic potential of CTNP's was further confirmed by clonogenic assay. Further in vivo studies using EAC mice model supports the anti-cancer potential of silver nanoparticles. Results found that the CTNP's effectively control the proliferation rate by inhibiting the ascites secretion and cellular density. Further quantification of VEGF, microvessel density counts and CAM assays show the anti-angiogenic potential of the CTNP's. The apoptotic inducing activity of CTNP's was confirmed by DNA fragmentation, fluorescent staining studies. More interestingly, EAC treated mice exhibit significant increase in lifespan (~ 2.25 fold) compared to control EAC mice. Interestingly CTNP's did not exhibit any secondary complications against normal mice. The present findings give an experimental proof that the CTNP's could serve as a promising candidate to overcome limitations of existing conventional cancer therapeutics.

中文翻译：

---

使用Clitoria ternatea花合成生物制备的银纳米颗粒的血管抑制作用：一种体外和体内方法。

研究了Clitoria ternatea花在水提取物中生物合成银纳米颗粒（CTNP）。合成的纳米粒子通过紫外可见光谱进行表征，然后使用DLS，Zeta电位，XRD，FTIR，SEM和AFM进行表征。CTNP's的生物相容性性质使用红细胞模型系统确定。用MTT法和台盼蓝排除法测定CTNP对MCF-7和EAC细胞的细胞毒性，IC50分别为19.37 µg / mL和24 µg / mL。通过克隆形成测定进一步证实了CTNP的细胞毒性潜力。使用EAC小鼠模型进行的进一步体内研究支持银纳米颗粒的抗癌潜力。结果发现，CTNP通过抑制腹水分泌和细胞密度有效控制增殖率。VEGF，微血管密度计数和CAM分析的进一步定量显示了CTNP的抗血管生成潜力。DNA片段化，荧光染色研究证实了CTNP的凋亡诱导活性。更有趣的是，与对照EAC小鼠相比，EAC处理的小鼠的寿命显着增加（约2.25倍）。有趣的是，CTNP对正常小鼠没有任何继发性并发症。本研究结果提供了实验证明CTNP可以作为克服现有常规癌症治疗方法局限性的有希望的候选者。更有趣的是，与对照EAC小鼠相比，EAC处理的小鼠的寿命显着增加（约2.25倍）。有趣的是，CTNP对正常小鼠没有任何继发性并发症。本研究结果提供了实验证明CTNP可以作为克服现有常规癌症治疗方法局限性的有希望的候选者。更有趣的是，与对照EAC小鼠相比，EAC处理的小鼠的寿命显着增加（约2.25倍）。有趣的是，CTNP对正常小鼠没有任何继发性并发症。本研究结果提供了实验证明CTNP可以作为克服现有常规癌症治疗方法局限性的有希望的候选者。